{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:08:13Z","timestamp":1778512093390,"version":"3.51.4"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["18ek0410025h0003"],"award-info":[{"award-number":["18ek0410025h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ejca.2020.02.044","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T12:19:05Z","timestamp":1585829945000},"page":"1-4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Toxic epidermal necrolysis accompanied by several immune-related adverse events developed after discontinuation of nivolumab"],"prefix":"10.1016","volume":"131","author":[{"given":"Yuko","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0297-6627","authenticated-orcid":false,"given":"Yukie","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Takamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukitoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Aihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.02.044_bib1","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.02.044_bib2","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jamadermatol.2018.1912","article-title":"Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy","volume":"154","author":"Wang","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2020.02.044_bib3","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1177\/1078155218791314","article-title":"Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy","volume":"25","author":"Hwang","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.ejca.2020.02.044_bib4","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/bjd.13162","article-title":"The serum level of HMGB1 (high mobility group box 1 protein) is preferentially high in drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms","volume":"171","author":"Fujita","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2020.02.044_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-beta 1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2020.02.044_bib6","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.02.044_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jdermsci.2016.12.019","article-title":"Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-\u03b1 is a biomarker of nivolumab recativity","volume":"86","author":"Tanaka","year":"2017","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.ejca.2020.02.044_bib8","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1172\/JCI31537","article-title":"A cytokine-mediated link between innate immunity inflammation, and cancer","volume":"117","author":"Lin","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2020.02.044_bib9","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.4049\/jimmunol.0803721","article-title":"IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells","volume":"183","author":"Goodman","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2020.02.044_bib10","first-page":"36","article-title":"GM-CSF as a therapeutic target in autoimmune diseases","volume":"5","author":"Shiomi","year":"2016","journal-title":"Inflamm Regen"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920301180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920301180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:09:46Z","timestamp":1778508586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920301180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":10,"alternative-id":["S0959804920301180"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.02.044","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxic epidermal necrolysis accompanied by several immune-related adverse events developed after discontinuation of nivolumab","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.02.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}